Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by ICICI Prudential Asset Management Co Ltd

ICICI Prudential Asset Management Co Ltd lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 19.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,018 shares of the company’s stock after acquiring an additional 809 shares during the quarter. ICICI Prudential Asset Management Co Ltd’s holdings in Moderna were worth $335,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in MRNA. Empowered Funds LLC grew its position in Moderna by 26.8% during the 1st quarter. Empowered Funds LLC now owns 4,276 shares of the company’s stock worth $456,000 after purchasing an additional 904 shares during the period. Atomi Financial Group Inc. acquired a new stake in Moderna during the first quarter worth about $225,000. Sei Investments Co. raised its position in Moderna by 16.4% during the first quarter. Sei Investments Co. now owns 84,910 shares of the company’s stock valued at $9,048,000 after acquiring an additional 11,977 shares in the last quarter. US Bancorp DE lifted its holdings in Moderna by 19.5% in the first quarter. US Bancorp DE now owns 23,107 shares of the company’s stock valued at $2,462,000 after acquiring an additional 3,771 shares during the period. Finally, Avantax Advisory Services Inc. lifted its holdings in Moderna by 53.3% in the first quarter. Avantax Advisory Services Inc. now owns 5,035 shares of the company’s stock valued at $537,000 after acquiring an additional 1,750 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

Shares of MRNA stock opened at $42.14 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a market capitalization of $16.22 billion, a PE ratio of -7.24 and a beta of 1.69. The firm’s 50-day moving average is $59.96 and its two-hundred day moving average is $97.80. Moderna, Inc. has a 12 month low of $41.54 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the prior year, the firm posted ($1.39) earnings per share. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. Analysts predict that Moderna, Inc. will post -9.34 earnings per share for the current year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of analyst reports. Sanford C. Bernstein started coverage on shares of Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective on the stock. Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and reduced their price target for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their price objective on Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a report on Monday, November 4th. Finally, Piper Sandler decreased their target price on Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, September 13th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $93.18.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.